Moleculin reports positive Annamycin combination data in pancreatic cancer models
Moleculin Biotech reported preclinical findings that Annamycin paired with PD-1 checkpoint inhibition improved survival in pancreatic cancer mouse models versus either treatment alone. The work, presented at a cancer research symposium on November 10, also found greater and more sustained pancreatic-tissue exposure than doxorubicin, along with increased immune-cell presence in tumors. Moleculin said it plans an investigator-initiated pancreatic cancer trial in 2027.
Why it matters
The findings support further testing of Annamycin outside its existing cancer programs, but they remain preclinical and do not establish a benefit in patients. The planned 2027 trial would be the next clinical step for this pancreatic cancer indication.
Key facts
- 1In a pancreatic cancer mouse model, Annamycin combined with PD-1 blockade increased survival compared with either agent used alone, with the finding reproduced in a second independent experiment. investing.com
- 2Pharmacokinetic testing found higher and more sustained pancreatic-tissue exposure for Annamycin than for doxorubicin at the same dose. investing.com
- 3Tumors treated with Annamycin showed increased infiltration by CD8+ cytotoxic T cells and CD4+ helper T cells. investing.com
- 4Moleculin said it is planning an investigator-initiated clinical trial of Annamycin for pancreatic cancer in 2027. investing.com
Open questions
- The company cautioned that the preclinical findings may not predict clinical outcomes in patients.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.